Robin Swartz Sells 3,087 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 3,087 shares of the stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $5.09, for a total transaction of $15,712.83. Following the transaction, the chief operating officer now directly owns 109,241 shares in the company, valued at approximately $556,036.69. This represents a 2.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Robin Swartz also recently made the following trade(s):

• On Monday, December 23rd, Robin Swartz sold 6,500 shares of Voyager Therapeutics stock. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00.

Voyager Therapeutics Stock Up 0.2 %

Shares of VYGR stock opened at $5.07 on Friday. The firm has a market capitalization of $276.97 million, a price-to-earnings ratio of 7.14 and a beta of 0.93. The stock has a fifty day moving average of $5.91 and a 200 day moving average of $6.72. Voyager Therapeutics, Inc. has a 52 week low of $4.99 and a 52 week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same period last year, the company posted ($0.59) EPS. Equities research analysts anticipate that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Institutional Trading of Voyager Therapeutics

Several large investors have recently bought and sold shares of VYGR. SG Americas Securities LLC raised its position in shares of Voyager Therapeutics by 86.7% in the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock worth $131,000 after acquiring an additional 10,704 shares in the last quarter. Barclays PLC grew its stake in Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after purchasing an additional 37,398 shares during the period. Geode Capital Management LLC raised its holdings in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after purchasing an additional 6,740 shares in the last quarter. Erste Asset Management GmbH purchased a new position in Voyager Therapeutics during the third quarter valued at $6,192,000. Finally, Verition Fund Management LLC bought a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $216,000. 48.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

VYGR has been the subject of a number of recent research reports. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $5.73 price target for the company. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $15.97.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.